Financements

Antiviral Drug Resistance in Avian Influenza Viruses, Canadian Institutes of Health Research Grant n°196781 (2024 - 2025)

Characterization of Seasonal Influenza Vaccination Cross-Type Activity on Avian H5Nx Canadian Institutes of Health Research Grant n°525159 (2024 - 2025)

Deciphering the Role of Antiviral Immune Mechanisms Among Respiratory viruses Canadian Institutes of Health Research Grant n°522807 (2024 - 2025)

Therapeutic Potential of Protectins for Influenza Infections Canadian Institutes of Health Research Grant n°522783 (2024 - 2025)

ANR AAPG2022 – MucRNAvax (2023-2026)

I-Demo régionalisé (bpi, région Auvergne-Rhône-Alpes, métropole de Grenoble) GESPPAIR (2023 – 2026)

International Research Program (IRP) CNRS (2023 - 2028)

Jointlab INSERM-Université Laval (2025 - 2029)

Programme ANTIVIRESPIR, Programmes et équipements prioritaires de recherche (PEPR) Maladies Infectieuses Émergentes France2030, infrastructure nationale Virocrib (2025 - 2028)

Essai clinique de phase 3 PIPELINE-RSV-France, ANRS-MIE ReCH-MIE 2023 France 2030 (2025 - 2028)

Important Projects of Common European Interest (IPCEI), End to End mRNA Vaccine (2026 - 2032)

Pour un meilleur contrôle des virus respiratoires émergents et ré-émergents

Nos axes de recherches
crossmenu